Matritech to Report First Quarter 2007 Financial Results on May 1, 2007
17 Avril 2007 - 2:00PM
Business Wire
Matritech (AMEX:MZT) announced today that it will release its first
quarter 2007 earnings results before market opening on May 1, 2007.
The company has scheduled a conference call at 8:30 a.m. (ET) that
day to discuss the results and provide a company update. The call
will be webcast and can be accessed on the Matritech web site at
www.matritech.com. Conference Call Dial-in Number To access the
conference call by phone, the dial-in number in the United States
is 800-291-9234. The International number is 617-614-3923. The
participant pass code is 50191288. The webcast will also be
distributed over CCBN's Investor Distribution Network to both
institutional and individual investors. About Matritech Matritech
is using its patented proteomics technology to develop diagnostics
for the detection of a variety of cancers. The Company's first two
products, the NMP22� Test Kit and NMP22� BladderChek� Test, have
been FDA approved for the monitoring and diagnosis of bladder
cancer. The NMP22 BladderChek Test is based on Matritech's
proprietary nuclear matrix protein (NMP) technology, which
correlates levels of NMPs in body fluids to the presence of cancer.
Beginning with a patent portfolio licensed exclusively from the
Massachusetts Institute of Technology (MIT), Matritech�s patent
portfolio has grown to 14 other U.S. patents. In addition to the
NMP22 protein marker utilized in the NMP22 Test Kit and NMP22
BladderChek Test, the Company has discovered other proteins
associated with cervical, breast, prostate, and colon cancer. The
Company�s goal is to utilize protein markers to develop, through
its own research staff and through strategic alliances, clinical
applications to detect cancer. More information about Matritech is
available at www.matritech.com. Statement under the Private
Securities Litigation Reform Act Any forward-looking statements in
this press release, including those related to the Company's
expectations regarding future sales of the Company�s products,
sales in specific target markets, future products under development
by the Company or third parties, and business prospects, are
subject to a number of risks and uncertainties, many of which are
beyond the Company�s control. Please refer to the risk factors
detailed in the Company's periodic reports and registration
statements as filed with the Securities and Exchange Commission.
These forward-looking statements are neither promises nor
guarantees. There can be no assurance that the Company's
expectations for its products or future financial performance will
be achieved. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. Matritech undertakes no responsibility to revise or update
any such forward-looking information.
Matritech (AMEX:MZT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Matritech (AMEX:MZT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Matritech, (American Stock Exchange): 0 recent articles
Plus d'articles sur Matritech